Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization
Interventions: Ketamine, Ketamine Injectable Product, Meaning and Purpose therapy, Placebo, Questionnaires; Drug · Behavioral · Other
Lead sponsor: Brian Anderson, MD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Androgenetic Alopecia
Interventions: 5% Minoxidil Topical Foam, Vehicle Topical Foam; Drug
Lead sponsor: Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 13
States / cities: Los Angeles, California • San Diego, California • Wichita, Kansas + 9 more

Conditions: Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Interventions: SGN-40, placebo, rituximab, etoposide, carboplatin, ifosfamide; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 24
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 21 more

Conditions: Asthma
Interventions: Dupilumab, Placebo; Drug · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Boston, Massachusetts • Detroit, Michigan • The Bronx, New York + 2 more

Conditions: Influenza, Common Cold, Cough, Headache, Fever
Interventions: Pomegranate, Placebo; Dietary Supplement
Lead sponsor: Texas Heart Institute; Other
Eligibility: 21 Years to 49 Years
Enrollment: 461 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hereditary Angioedema
Interventions: rhC1INH, Placebo (Saline); Drug
Lead sponsor: Pharming Technologies B.V.; Industry
Eligibility: 13 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 15
States / cities: Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 12 more

Conditions: Pediatric Traumatic Brain Injury
Interventions: Probenecid and N-acetyl cysteine, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 2 Years to 18 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Idiopathic Hypersomnia
Interventions: JZP-258, Placebo Oral Solution; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 40
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more

Conditions: Shoulder Joint Disease, Complications; Arthroplasty, Intraoperative Complications, Blood Loss, Surgical
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Asthma
Interventions: MN-221, Placebo; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 4
States / cities: Lenexa, Kansas • North Dartmouth, Massachusetts • Rolla, Missouri + 1 more

Conditions: Chronic Pain
Interventions: Kindolor Tosylate, Placebo; Drug
Lead sponsor: Lohocla Research Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Active Ethanol and Active Iomazenil, Active Ethanol and Placebo Iomazenil, Placebo Ethanol and Active Iomazenil, Placebo Ethanol and Placebo Iomazenil, Alcohol Effect, Driving Under the Influence, Alcohol Impairment
Interventions: Active Ethanol, Active Iomazenil, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 35 Years · Male only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Alopecia Areata
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 50
States / cities: Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 41 more

Conditions: This Study Will Evaluate Whether TXA Reduces Pain
Interventions: Tranexamic acid, placebo; Drug · Other
Lead sponsor: St. Louis Joint Replacement Institute; Other
Eligibility: Not listed
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Bridgeton, Missouri

Conditions: Acute Pain
Interventions: Ketamine, Morphine, placebo; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 100 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Sepsis
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: Jonathan Sevransky; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions: Pegcetacoplan (APL-2), Placebo; Drug · Other
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more

Conditions: Respiratory Syncytial Virus Infections, Virus Diseases
Interventions: JNJ-53718678, Placebo; Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 1 Month to 24 Months
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Kirksville, Missouri

Conditions: Foot Ulcer, Diabetic, Infection
Interventions: Gentamicin Collagen sponge, Placebo; Drug · Other
Lead sponsor: Innocoll; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 524 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Anniston, Alabama • Las Vegas, Nevada

Conditions: Stress Urinary Incontinence
Interventions: BTL Emsella, Sham BTL Emsella; Device
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years to 80 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Insulin Resistance, Impaired Glucose Tolerance, Prediabetes
Interventions: Cassia cinnamon, 50 minutes exercise, Cellulose Powder; Dietary Supplement · Procedure
Lead sponsor: Baylor University; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Waco, Texas

Conditions: Epilepsy, Essential Tremor, Seizures, Memory Consolidation, Memory Disorders, Memory Replay, Memory Encoding, Cognitive Control, Motor Abilities
Interventions: Cobenfy KarXT pill (50/20 mg), Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Rheumatoid Arthritis
Interventions: Infliximab, Methotrexate, Methylprednisolone, Ocrelizumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 53
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more

Conditions: Cigarette Smoking, Alcohol Consumption
Interventions: Varenicline, Placebo pill (for varenicline), Alcohol, placebo beverage (for alcohol); Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Ketamine-assisted Therapy for Advanced GI Cancer

Clinical Trial in Females for Female Pattern Hair Loss

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Investigating Dupilumab's Effect in Asthma by Genotype

Pomegranate Products for Prevention of Common Cold

Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury

A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

Tranexamic Acid in Reverse Total Shoulder Arthroplasty

Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults

Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Effect of Tranexamic Acid (TXA) Administered Prior to Shoulder Arthroscopy on Postoperative Pain Medication Usage: A Randomized Controlled Trial

Ketamine and Morphine Versus Morphine Alone for the Treatment of Acute Pain in the Emergency Department

Alirocumab in Patients with Sepsis

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection

Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers

BTL Emsella Chair Versus Sham for the Treatment of Stress Urinary Incontinence

Cassia Cinnamon for Glucose Uptake in Young Women

Human Cognition During Surgery: Stimulation-based and Cholinergic Modulation

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab

Effects of Varenicline in Heavy Drinking Smokers